Modern Chinese Medicine turns to FY26 H1 net loss of RMB 25.9 million; revenue rises 82.9% to RMB 118.5 million

• Modern Chinese Medicine posted a loss attributable to owners of RMB 25.9 million for the six months ended June 30, swinging from a profit.
• Revenue rose 82.9% to RMB 118.5 million, driven by higher orders from Hong Kong and mainland China distributors.
• Gross profit increased 36.4% to RMB 22.1 million; gross margin fell 6.3 percentage points to 18.7%.
• Selling and distribution expenses more than tripled to RMB 33.4 million on higher promotion and marketing spend; R&D costs were RMB 15.3 million.
• Completed acquisition of a 30% stake in AI Health Global, adding Hong Kong-registered traditional Chinese medicine products and e-commerce channels for overseas expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306444), on August 28, 2026, and is solely responsible for the information contained therein.